DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Lucitanib is an investigational drug.
There have been 8 clinical trials for Lucitanib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Bristol-Myers Squibb.
There are twelve US patents protecting this investigational drug and ninety-eight international patents.
Recent Clinical Trials for Lucitanib
|A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy||Bristol-Myers Squibb||Phase 1/Phase 2|
|A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor||Bristol-Myers Squibb||Phase 1/Phase 2|
|A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor||Clovis Oncology, Inc.||Phase 1/Phase 2|
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lucitanib||Start Trial||Human anti-VEGFR-2/KDR antibodies||KADMON CORPORATION, LLC (New York, NY)||Start Trial|
|Lucitanib||Start Trial||Rho kinase inhibitors||KADMON CORPORATION, LLC (New York, NY)||Start Trial|
|Lucitanib||Start Trial||Rho kinase inhibitors||Kadmon Corporation, LLC (New York, NY)||Start Trial|
|Lucitanib||Start Trial||Human anti-VEGFR-2/KDR antibodies||Kadmon Corporation, LLC (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Lucitanib||Eurasian Patent Organization||032679||2032-10-05||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|